Omnicell, Inc.
Nov 24, 2015

Omnicell To Discuss Aesynt Acquisition At The 27th Annual Piper Jaffray Health Care Conference

Aesynt LTM 9/30/15 revenue and adjusted EBITDA at $190 million and $23 million, respectively, up from $182 million and $20 million for LTM 6/30/15

MOUNTAIN VIEW, Calif., Nov. 24, 2015 /PRNewswire/ -- Omnicell, Inc. (NASDAQ: OMCL) a leading provider of medication and supply management solutions and analytics software for health care facilities, today announced they will present at the 27th Annual Piper Jaffray Health Care Conference at the New York Palace Hotel, New York, NY. 

Omnicell, Inc. logo.

Omnicell previously announced that it had entered into a definitive agreement to acquire Aesynt. The acquisition would create the broadest product portfolio in the industry with significant offerings in automated dispensing systems, central pharmacy robotics, IV robotics and enterprise analytics.  The combined entity would support approximately 4,000 acute care facilities worldwide, have annual revenues of over $650 million and have approximately 2,200 employees.

Details of the acquisition will be discussed at the conference and are also included in an investor presentation found in the investor relations section of our website.  The investor presentation can also be accessed by clicking here.

Speakers: Randall A. Lipps, founder, chairman, president & CEO Omnicell, and Kraig McEwen, CEO Aesynt

Date: Tuesday, December 1, 2015
Time: 2:30 p.m. ET
Location: New York Palace Hotel, New York, NY
Availability: The audio-webcast of the live presentation may be accessed by visiting:
http://ir.omnicell.com/events.cfm

Following the conference, a replay of the audio-webcast will be archived for 30 days on the Omnicell website.

About Omnicell

Since 1992, Omnicell (NASDAQ: OMCL) has been creating new efficiencies to improve patient care, anywhere it is delivered. Omnicell is a leading supplier of comprehensive automation and business analytics software for patient-centric medication and supply management across the entire health care continuum— from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home.

More than 3,200 customers worldwide have utilized Omnicell Automation and Analytics solutions to increase operational efficiency, reduce errors, deliver actionable intelligence and improve patient safety. Omnicell Medication Adherence solutions, including its MTS Medication Technologies brand, provide innovative medication adherence packaging solutions to help reduce costly hospital readmissions. In addition, these solutions enable approximately 7,000 institutional and retail pharmacies worldwide to maintain high accuracy and quality standards in medication dispensing and administration while optimizing productivity and controlling costs.

Logo - http://photos.prnewswire.com/prnh/20120731/SF48971LOGO-a

OMCL-G

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/omnicell-to-discuss-aesynt-acquisition-at-the-27th-annual-piper-jaffray-health-care-conference-300183843.html

SOURCE Omnicell, Inc.

News Provided by Acquire Media